$0.09
(0.78%)
0.60%
Create an alert
Stocks and Shares ISAPhathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.
Company Information
About this company
Key people
Michael F. Cola
Independent Chairman of the Board
Steven Basta
President, Chief Executive Officer, Director
Sanjeev Narula
Chief Financial and Business Officer
Anne Marie Cook
Chief Legal Officer and Corporate Secretary
Frank L. Karbe
Independent Director
Heidi K. Kunz
Independent Director
Asit Parikh
Independent Director
Theodore R. Schroeder
Independent Director
Click to see more
Key facts
- Shares in issue79.76m
- EPICPHAT
- ISINUS71722W1071
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$907.62m
- Employees371
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.